latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/zai-lab-to-commercialize-regeneron-s-cancer-drug-in-greater-china-57957540 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Zai Lab to commercialize Regeneron's cancer drug in Greater China

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Zai Lab to commercialize Regeneron's cancer drug in Greater China

Shanghai-based Zai Lab Ltd. acquired the rights to develop and commercialize Regeneron Pharmaceuticals Inc.'s cancer drug REGN1979 in Greater China.

REGN1979 is a bispecific antibody that is being tested in patients with B cell non-Hodgkin lymphoma, the most common type of blood cancer.

Zai Lab is making an up-front payment of $30 million for the rights, and agreed to pay up to a further $160 million if the medicine meets certain milestones. Zai Lab will also contribute to the global development costs of some REGN1979 trials.

New York-based Regeneron will manufacture and supply the drug for development and commercialization in the regions covered: China, Hong Kong, Taiwan and Macau.

The experimental drug holds the orphan drug designation in the U.S. Food and Drug Administration to treat follicular lymphoma and diffuse large B-cell lymphoma, the companies said in a press release.